InvestSMART

Nexalis Therapeutics Ltd (ASX: NX1) - Share Price

- Current share price for NX1 : $0.011

Nexalis Therapeutics Ltd (NX1, formerly Inhalerx Limited), an ASX-listed company,, is an Australian Clinical Stage Drug Development Company that is developing onset, inhaled therapies to address unmet medical needs in pain management and mental health sectors.

NX1 General Information +

ASX Code NX1
Website http://www.nexalistherapeutics.com
Industry/Sector Pharmaceuticals
Market Cap ($M) 2
NX1 Share Price $0.011
Day High $0.011
Day Low $0.011
Last Close $0.011
NX1 Share Price Movement - ( No change )
Prices as at 16:35, 24 Jul 2026
+Security prices are delayed by at least 20 minutes and are indicative only.

Nexalis Therapeutics Ltd (NX1) Upcoming Dividends & Yields

Distribution Type Dividend Franking Ex-dividend date Payment date Current Price+ Price 7D Avg Dividend Yield

See all dividends from Nexalis Therapeutics Ltd (NX1) or use our Upcoming Dividends tool to search for dividends across all ASX-listed securities.

Nexalis Therapeutics Ltd (NX1) price-sensitive announcements

NX1 - Update on Funding Facility and Clinical Program
Nexalis Therapeutics Ltd (NX1), based in Melbourne, Australia, provided an update on its f
Nexalis Therapeutics Ltd (NX1)
6 Jul 2026 | 11:48 AM
NX1 - Reinstatement to Official Quotation
Nexalis Therapeutics Ltd, trading under the code ASX: NX1, has been reinstated to official
Nexalis Therapeutics Ltd (NX1)
28 May 2026 | 9:48 AM
NX1 - Binding Letter of Intent to replace existing $53m facility
Nexalis Therapeutics Ltd has entered into a binding letter of intent with Point8 Capital P
Nexalis Therapeutics Ltd (NX1)
28 May 2026 | 9:48 AM
NX1 - Suspension from Quotation
On 26 May 2026, Nexalis Therapeutics Ltd (ASX: NX1) announced the suspension of its securi
Nexalis Therapeutics Ltd (NX1)
26 May 2026 | 10:34 AM

Nexalis Therapeutics Ltd (NX1) Recent ASX Announcements

Company Sector Market Cap ($m) Headline Release
date/time+
Price at
release+
Current
price+
Gain/Loss View
Nexalis Therapeutics Ltd (NX1)
ORDINARY FULLY PAID
Health Care $3 Change of Director's Interest Notice - Sean Williams 14 Jul 2026 3:13PM $0.010 $0.011 risen by 10%
Nexalis Therapeutics Ltd (NX1)
ORDINARY FULLY PAID
Health Care $3 Change of Director's Interest Notice - Darryl Davies 14 Jul 2026 3:12PM $0.010 $0.011 risen by 10%
Nexalis Therapeutics Ltd (NX1)
ORDINARY FULLY PAID
Health Care $3 Notification of cessation of securities - NX1 14 Jul 2026 3:10PM $0.010 $0.011 risen by 10%
Nexalis Therapeutics Ltd (NX1)
ORDINARY FULLY PAID
Health Care $3 Notification regarding unquoted securities - NX1 14 Jul 2026 3:10PM $0.010 $0.011 risen by 10%
Nexalis Therapeutics Ltd (NX1)
ORDINARY FULLY PAID
Health Care $3 Issue of director share rights post shareholder approval 14 Jul 2026 3:06PM $0.010 $0.011 risen by 10%
Nexalis Therapeutics Ltd (NX1)
ORDINARY FULLY PAID
Health Care $3 Update on Funding Facility and Clinical Program 6 Jul 2026 11:48AM $0.010 $0.011 risen by 10%

NX1 Financial Summary

Year to Dec NPAT EPS EPS chg (%) PER DPS Yield (%) Franking (%)
2025A -$1.62 -$0.80 31.60% 0.00 0.00 0.00% 0.0%
2024A -$1.21 -$0.60 -24.00% 0.00 0.00 0.00% 0.0%
2023A -$1.43 -$0.80 -31.80% 0.00 0.00 0.00% 0.0%

NX1 Peer Comparison

Company Mkt Cap EPS Growth (%) P/E (%) Dividend Yield (%)
2023 A 2024 A 2025 A 2023 A 2024 A 2025 A 2023 A 2024 A 2025 A
Clarity Pharmaceuticals Ltd (CU6) $873M 0.3002 0.0000 0.0000 0.0000 0.0000 0.0000 0.00% 0.00% 0.00%
Neuren Pharmaceuticals Limited (NEU) $2,192M -0.7857 0.0743 1.2000 74.3017 69.1600 31.4364 0.00% 0.00% 0.00%
Nexalis Therapeutics Ltd (NX1) $3M 0.3158 0.0000 0.0000 0.0000 0.0000 0.0000 0.00% 0.00% 0.00%

NX1 Market Comparison

Earnings P/E Ratio P/B Ratio P/E Growth
Company 0.00 0.00 -2.75 0.00
Market 0.31 12.90 1.14 0.59
Sector 0.43 30.10 2.48 2.50

NX1 Directors

Name Position Start Date
Mr Darryl Davies Chief Executive Officer, Executive Director 20 Jul 2021
Mr James Stephen Barrie Company Secretary, Executive Director 1 Mar 2024
Mr Sean Williams Non-Executive Chairman, Non-Executive Director 26 Jul 2021

Nexalis Therapeutics Ltd (NX1) Changes in Directors' Interest & Trades

Date of change Director Buy/Sell Security Type Qty Trade Price Value
14 Jul 2026 WILLIAMS, Sean Issued Related Securities 2,641,477 $0.016 $42,263.632
17 Feb 2026 WILLIAMS, Sean Issued Related Securities 1,851,567 $0.023 $42,586.041
17 Feb 2026 WISE, Ronald Issued Indirect Shares 1,400,000 $0.025 $35,000.000

See all changes in directors' interest & trades for Nexalis Therapeutics Ltd (NX1) or use our Changes in directors' interest tool to search for changes & trades across all ASX-listed securities.

NX1 Substantial Shareholders

Under ASX rules large investors and investment funds must disclose when they own more than a 5% stake in Nexalis Therapeutics Ltd (NX1). However, you won't necessarily see their names in the company’s annual report, as many trade under nominee names. These shareholders are obliged to provide ongoing substantial notices relating to any change of 1% or more.

Holding Name
48,330,887 (19.10%) Cannvalate Pty Ltd
31,739,967 (12.54%) 10 Bolivianos Pty Ltd
18,949,999 (7.49%) Pyxis Holdings Pty Ltd

DISCLOSURE: InvestSMART Group Limited employees may have an interest in the securities and managed funds displayed via this service. Please refer to our Financial Services Guide for more information.

Data shown on this website is sourced by Morningstar
© Morningstar. All rights reserved. Neither any Morningstar company nor any of their content providers guarantee the data or content contained herein to be accurate, complete or timely nor will they have any liability for its use or distribution. Any general advice has been prepared by Morningstar Australasia Pty Ltd (ABN: 95 090 665 544, AFSL: 240892) and/or Morningstar Research Limited, subsidiaries of Morningstar, Inc, without reference to your objectives, financial situation or needs. You should consider the advice in light of these matters and, if applicable, the relevant Product Disclosure Statement (in respect of Australian products) or Investment Statement (in respect of New Zealand products) before making any decision to invest. No Morningstar-affiliated company or any of their employees is providing you with personalised financial advice. To obtain advice tailored to your particular circumstances, please contact a professional financial adviser. Some material is copyright and published under licence from ASX Operations Pty Limited ACN 004 523 782 ("ASXO"). Data and content is provided for personal use only.